Cargando…

Prognostic implications of HER2 heterogeneity in gastric cancer

The prognostic implications of human epidermal growth receptor 2 (HER2) heterogeneity in gastric cancer (GC) are not well established. Therefore, the aim of the present study was to determine to the effect of HER2 status on the prognosis of GC patients. We retrieved data on 248 pathologically-confir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Motoshima, Shigenobu, Yonemoto, Koji, Kamei, Hideki, Morita, Michi, Yamaguchi, Rin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823644/ https://www.ncbi.nlm.nih.gov/pubmed/29507688 http://dx.doi.org/10.18632/oncotarget.24265

Ejemplares similares

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
por: Kaito, Akio, et al.
Publicado: (2019)

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
por: Nonagase, Yoshikane, et al.
Publicado: (2016)

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
por: Wakatsuki, Takeru, et al.
Publicado: (2018)

CD8(+) tumor‐infiltrating lymphocytes contribute to spontaneous “healing” in HER2‐positive ductal carcinoma in situ
por: Morita, Michi, et al.
Publicado: (2016)

Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer
por: Stahl, Phillip, et al.
Publicado: (2015)

HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature
por: Jørgensen, Jan Trøst, et al.
Publicado: (2012)

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
por: Yagi, Shusuke, et al.
Publicado: (2018)

HER2 Expression in Gastric Cancer: Rare, Heterogeneous and of No Prognostic Value – Conclusions from 924 Cases of Two Independent Series
por: Grabsch, Heike, et al.
Publicado: (2010)

HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists
por: Fusco, Nicola, et al.
Publicado: (2016)

Temporal heterogeneity of HER2 expression in metastatic gastric cancer: a case report
por: Zhang, Qi, et al.
Publicado: (2022)

HER2 Status and Its Heterogeneity in Gastric Carcinoma of Vietnamese Patient
por: Phan, Dang Anh Thu, et al.
Publicado: (2017)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer
por: Muroya, Daisuke, et al.
Publicado: (2016)

HER2 Heterogeneity in Gastric Cancer: A Comparative Study, Using Two Commercial Antibodies
por: Satala, Catalin Bogdan, et al.
Publicado: (2020)

HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients
por: Halon, Agnieszka, et al.
Publicado: (2012)

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
por: Kim, Chan, et al.
Publicado: (2017)

Her2-Positive and Microsatellite Instability Status in Gastric Cancer—Clinicopathological Implications
por: Bermúdez, Ana, et al.
Publicado: (2021)

Therapeutic implication of HER2 in advanced biliary tract cancer
por: Nam, Ah-Rong, et al.
Publicado: (2016)

Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer
por: Dai, Lei-Jie, et al.
Publicado: (2023)

Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
por: Cao, Guo-dong, et al.
Publicado: (2017)

Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer
por: Ema, Akira, et al.
Publicado: (2014)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

HER2-positive gastric cancer
por: Boku, Narikazu
Publicado: (2013)

Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer
por: Yang, Tao, et al.
Publicado: (2022)

Low frequency of HER2 amplification and overexpression in early onset gastric cancer
por: Moelans, Cathy B., et al.
Publicado: (2011)

Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer
por: Chen, Ming, et al.
Publicado: (2014)

Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases
por: De Mattos-Arruda, Leticia, et al.
Publicado: (2018)

The Prognostic Significance of Her2-Neu Over expression in Gastric Carcinomas
por: Ansari, J, et al.
Publicado: (2011)

Quantification of HER2 heterogeneity in breast cancer–implications for identification of sub-dominant clones for personalised treatment
por: Buckley, Niamh E., et al.
Publicado: (2016)

Significance of tumor heterogeneity of p-Smad2 and c-Met in HER2-positive gastric carcinoma with lymph node metastasis
por: Tsujio, Gen, et al.
Publicado: (2022)

Diffusion-weighted MR imaging in gynecologic cancers
por: Motoshima, Shigenobu, et al.
Publicado: (2011)

Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas
por: Tang, Daoqiang, et al.
Publicado: (2014)

Oncogenic HER2 fusions in gastric cancer
por: Yu, De-Hua, et al.
Publicado: (2015)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer
por: Yoshioka, Takahiro, et al.
Publicado: (2018)

Dissecting the biological heterogeneity of HER2-positive breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept
por: Hou, Yanjun, et al.
Publicado: (2023)

Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression
por: Pye, Hayley, et al.
Publicado: (2018)

Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment
por: Baker, Jennifer Hazel Elizabeth, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l1ufnp5g87l3puv5pqku32ukk2